Medtronic plc logo
Medtronic plc (MDT)
Compare

Medtronic plc (MDT) Net Income

The annual net income for Medtronic plc (MDT) is $4.80 Billion with a year-over-year change of +2.96%. Net income represents the company's bottom line profit after all expenses, taxes, and interest.

Annual Net Income (TTM)

$4.80B

$4.80 Billion

Year-over-Year Change

+2.96%

vs. $4.66B prior year

Net Income CAGR

+10.17%

5 Year compound annual growth rate

Net Income CAGR (Compound Annual Growth Rate)

1 Year

+10.05%

3 Year

+5.28%

5 Year

+10.17%

10 Year

+6.86%

15 Year

+2.54%

20 Year

+4.42%

CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.

Annual Net Income History

YearNet IncomeYoY Change% Change
2026$4.80B+$138.00M+2.96%
2025$4.66B+$986.00M+26.82%
2024$3.68B($82.00M)(2.18%)
2023$3.76B($1.28B)(25.42%)
2022$5.04B+$1.43B+39.74%
2021$3.61B($1.18B)(24.70%)
2020$4.79B+$158.00M+3.41%
2019$4.63B+$1.53B+49.19%
2018$3.10B($924.00M)(22.94%)
2017$4.03B+$490.00M+13.85%

Net Income Growth Summary

TTM Growth

+10.05%

3-Year Avg Growth

+5.28%

5-Year Avg Growth

+10.17%

Data as of Wednesday, June 10, 2026

About Medtronic plc

Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.

Galway
95,000 employees
Healthcare / Medical - Devices
Sector
Healthcare
Industry
Medical - Devices
CEO
Geoffrey Straub Martha